Date post: | 29-Mar-2015 |
Category: |
Documents |
Upload: | kenneth-havey |
View: | 214 times |
Download: | 0 times |
Rx Communications Group, LLCCapabilities Overview
2000 – 2014: Providing award-winning communications counsel to life sciences and health care companies
ABOUT Rx COMMUNICATIONS
Specialists in the life science and health care industries
Partner-driven -- Senior level counsel on EVERY account
Navigate clients through up and down market cycles, various political health care agendas and technology trends
ABOUT Rx COMMUNICATIONS
Experience with private and public companies – domestic and international
Focused on what we do best: Investor Relations and Financial/Science Media Relations
Strong Wall Street and media contacts
Headquartered in New York City
PRIVATE COMPANIES
Services for Private Companies
WHY EMBARK ON AN IR/PR PROGRAM AS A PRIVATE COMPANY? Lay the groundwork for future
financings and eventual IPO
Assist with partnering activities by building corporate awareness
Build awareness of disease indications to generate product interest
Align company with reputable bankers
Become accustomed to working within disclosure rules i.e., Reg. FD
PROVIDING VALUE TO PRIVATE COMPANIES
Develop key messages positioned for analysts and investors
Develop collateral materials to tell story integrating key messages
Target and facilitate introductions to venture capitalists and institutional investors
Target and advise on corporate finance team
Target and facilitate introductions to sell-side analysts
PROVIDING VALUE TO PRIVATE COMPANIES
Build presence on the web
Review upcoming newsworthy events and develop story ideas for the media
Cultivate reporter interest
Introduce to conference circuit
Strategically position company news to optimize impact
Develop company disclosure policy
ACTIVITIES SUROUNDING IPO
Assist in the selection of banking team – beginning of quiet period
Press release announcing registration for offering
Develop roadshow presentation
Supplement banker’s list of target institutions
Presentation training
ACTIVITIES SURROUNDING IPO
“Teach-ins” at banks
Roadshow
Press release announcing completion of IPO
“Welcome letter” to new shareholders
Create disclosure policy
Quiet period compliance
PUBLIC COMPANIES
Services for Public Companies
AFTER-MARKET SUPPORT
Need for continual dialogue with shareholders
Ongoing targeting of investors for future financings
Increase analyst coverage beyond banking support
Fulfill disclosure requirements
Crisis communications
Strategic media outreach
GETTING STARTED: FIRST STEPS
Strategy session in order to immerse ourselves in corporate story
Define key message points
Understand perceptions existent in the marketplace
Create targeted list of sell-side analysts, venture capitalists and fund managers
GETTING STARTED: FIRST STEPS
Review collateral materials
Create VIP blast e-mail/fax lists
Develop media lists
Design action plan
Rx COMMUNICATIONS CAPABILITIES
Strategic Counsel Roadshows Analyst Contact Investor Targeting Investment and Industry Conferences Follow-up and Analysis to Key Events Press Release Writing News Conferences/Press Briefings Video/Radio News Releases Fact Sheets Annual Reports
Rx COMMUNICATIONS CAPABILITIES
Crisis Communications Mergers and Acquisitions Positioning Strategy Perception Audits Conference Calls Presentation Training Placement Strategy Financial, Trade and Local Media
Contacts Slide Presentations Web Site Development
THE Rx TEAM
Melody A. Carey, Co-President
Founded Rx Communications in 2000
Head of Corporate Communications and Spokesperson, Schein Pharmaceutical, Inc.
Director of Investor Relations, The Multicare Companies, Inc.
Executive, Noonan/Russo Communications
Former health care/life sciences investment banker, Kidder, Peabody & Co.
THE Rx TEAM
Rhonda Chiger, Co-President
Founded Rx Communications in 2000
Senior Managing Director, Global Consulting Practice, Thomson Financial
Managed Life Sciences departments for Noonan/Russo and Dewe Rogerson
Established London office for health care investor relations firm
Manager, Investor Relations, American Stock Exchange
THE Rx TEAM
Eric Goldman, Vice President
Six years with Rx Communications
25 years experience in public relations and as a media relations strategist specializing in biotechnology, health care, technology and consumer products
Senior Director and Vice President at GlobalFluency
Handled media relations at Spector & Associates and Brouillard Communications, a division of J. Walter Thompson
Earned 2 Silver Anvil awards for public relations excellence
THE Rx TEAM
Paula B. Schwartz, Senior Vice President
Ten years with Rx Communications
Partner, FRB/Weber Shandwick, oldest and largest Investor Relations firm in the U.S.
Vice President, ECOM Consultants, Inc., an investor relations firm
Vice President/Director of Investor Relations Programs, KCS&A Public Relations, a public relations and investor relations consultancy
Rx COMMUNICATIONS CURRENT CLIENT LIST ActoGeniX NV (Private)
Alexandria Real Estate Equities, Inc. (NYSE: ARE)
Alexion Pharmaceuticals Inc. (Nasdaq: ALXN)
Bio-Path Holdings, Inc. (Nasdaq: BPTH)
Ikaria, Inc. (Private)
InnoPharma, Inc. (Private)
Intact Medical Corporation (Private)
MAXIMUS, Inc. (NYSE: MMS)
MolMed S.p.A. (Milan: MLM)
Rx COMMUNICATIONS CURRENT CLIENT LIST
Nanotherapeutics, Inc. (Private)
Neurotrope, Inc. (OTCQB: NTRP)
Ophthotech Corporation (Nasdaq: OPHT)
Oxford BioMedica plc (LSE: OXB)
Orexo AB (OTCQX: ORXOY)
PharmAthene, Inc. (NYSE MKT: PIP)
Photocure (OSE: PHO)
Sigma-Tau Pharmaceuticals, Inc. (Private)
StemBioSys Inc. (Private)
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL)
OURx SUCCESSES
Helped to grow Alexion Pharmaceuticals’ institutional shareholder base from 30% in 1996 to approximately 95% today.
Launched not-for-profit Immune Tolerance Institute resulting in broad coverage in the U.S. including CBS Radio Network, San Francisco Business Times and Drug Discovery News.
Garnered coverage for Catalyst Pharmaceutical Partners’ compound for cocaine addiction. Placements included cover stories in Newsweek, Scientific American Mind and NeuroInvestment.
OURx SUCCESSES
Designed and implemented assertive investor outreach program for PDI which doubled trading volume and tripled its stock price within nine months.
Arranged feature coverage focused on Hodgkins and non-Hodgkins lymphoma for MethylGene with Genetic Engineering News, Pink Sheet, BioCentury and Pharmawire
Implemented aggressive IR program for PharmAthene, Inc. which enabled the company to obtain coverage from two new sell-side analysts, garner investments from four new institutional funds and increase trading volume by three-fold within nine months.
OURx SUCCESSES
Generated feature articles with Dow Jones Newswire, BioWorld Today, FierceBiotech for the TetraLogic Pharmaceuticals Series C financing.
Devised communications campaign to increase visibility of Amorcyte’s enriched bone marrow stem cell therapy by maximizing clinical data presented at American College of Cardiology (ACC) conference. Leveraged key opinion leaders who presented Amorcyte’s data to gain media coverage, surpassing competitors with later stage clinical data and larger operating budgets. News coverage included: Reuters, CBS Radio Network, Start-Up Magazine & Pharmawire.
OURx SUCCESSES
Generated news coverage with Dow Jones Newswire, Wall Street Journal.com, Drug Discovery & Development for launch of Neovacs autoimmune disease therapeutics.
Developed compelling key messages and arranged media interviews surrounding ZIOPHARM Oncology sarcoma clinical trials resulting in news coverage from Bloomberg Television, Reuters Newswire, BusinessWeek, Associated Press, Wall Street Journal and Forbes.
Within nine months, re-positioned MAXIMUS from a business processing company to a health care services company. Garnered health care sell-side research coverage from Bank of America and Citigroup Global Markets.
OURx SUCCESSES
We are pleased to announce that RxCommunications has been selected by PR Week
as a finalist forBoutique PR Agency of the Year
Rx Communications was named Best Small PR Agency
by League of American Communications Professionals
Rx Communications Group was honored with theStevie Award for Best Investor Relations
Program for work on behalf of specialty
pharmaceutical company, NexMed, Inc.
OURx SUCCESSES
Rx Communications was honored with the SABREAwards Certificate of Excellence for Building a North
American Investor Base for client Syngenta AG.
We are also pleased to share that our work for ImpactRx has won an Honorable Mention
Award in LACP’s (League of AmericanCommunications Professionals) Publicity
Campaign Competition.
Rx Communications received an honorable MentionAward from PR News, as part of the PR News Platinum PR
Awards. The award was issued in theFinancial/Investor Relations category, for the company's
work on behalf of Genaissance Pharmaceuticals, Inc.
WHY Rx COMMUNICATIONS?
Specialist industry knowledge and expertise
Personal attention from Rx partners
Decades of experience in strategic counsel and implementation of financial public relations programs
Unique niche in working with private companies
Well versed in IPOs, secondary offerings, PIPEs, venture rounds and mergers and acquisitions
“The Street” knows and trusts us
For Additional Information:Rx Communications Group, LLC
555 Park Avenue5th Floor
New York, NY 10022(917) 322-2568www.RxIR.com